Evidence map›Paper›PMID 41817383›Full record

ArticleCPT: pharmacometrics & systems pharmacology2026

Impact of Event-Related Treatment Modifications in Exposure-Response Analyses of Repeated Time-to-Event Data.

Sebastiaan Camiel Goulooze, Nelleke Snelder, Thomas Eissing, Dirk Garmann

Abstract read
In one paragraph

Article in CPT: pharmacometrics & systems pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Sebastiaan Camiel GouloozeLAP&P Consultants BV, Leiden, the Netherlands.ORCID https://orcid.org/0000-0003-3369-6107
Nelleke SnelderLAP&P Consultants BV, Leiden, the Netherlands.ORCID https://orcid.org/0000-0003-1302-678X
Thomas EissingBayer AG, Pharmaceuticals R&D, Model-Informed Drug Development, Leverkusen, Germany.ORCID https://orcid.org/0000-0003-4378-3423
Dirk GarmannBayer AG, Pharmaceuticals R&D, Model-Informed Drug Development, Leverkusen, Germany.ORCID https://orcid.org/0009-0003-5926-3980

Funding

Bayer AG, Wuppertal, Germany
6 · The paper itself

Abstract

Exposure-response (ER) analyses of repeated time-to-event (RTTE) data can be confounded when treatment modifications occur due to the event of interest. One particularly challenging scenario is when an event is preceded by an undocumented clinical worsening leading to treatment discontinuation shortly before the event. Event-related treatment modifications introduce potential reversed causality in the ER analysis and bias, as events may predict exposure, rather than exposure predicting events. We systematically evaluated three analysis approaches in multiple simulated placebo-controlled studies to assess their capacity to estimate unbiased ER relationships: (1) average exposure (2) time-varying exposure (3) average exposure + percentile-rank of the average amount of blinded study treatment received. The novel Approach 3 was designed to remove confounding from event-related treatment modifications by leveraging information on blinded study treatment received (including in the placebo treatment arm). Approach 1 was biased in all scenarios with event-related treatment discontinuations. Approach 2 generally resulted in unbiased estimates, except in the scenarios in which events were sometimes preceded by a treatment discontinuation. In these scenarios, only Approach 3 provided unbiased estimates with linear ER, though it showed slight bias with pronounced nonlinear relationships. In conclusion, treatment modifications associated with events warrant careful consideration in ER analyses of RTTE data. Using a ranked measure of the average amount of blinded study treatment received may be used to lower the risk of confounding due to treatment modifications.

Indexed as

Time-to-TreatmentBiasComputer SimulationConfounding Factors, EpidemiologicHumansTime Factorsconfoundingdose titrationexposure‐responsepopulation pharmacokinetic‐pharmacodynamic modelingrepeated time‐to‐event modelingtreatment discontinuationtreatment modification

Identifiers

PMID41817383
PMCPMC13097640

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.